Nkarta, Inc.
NKTXHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeNkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. With a market capitalization of $184.6M, it sits in micro-cap territory. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis.
Market Cap
$184.6M
Beta
0.92
P/E (TTM)
—
P/E (Fwd)
-1.56
EPS (TTM)
$-1.35
EPS (Fwd)
$-1.65
ROE
-30.1%
ROA
-17.1%
Cash
$230.4M
Total Debt
$75.0M
Free CF
-$57.4M
52W Change
24.0%
Annual Financials
Cash vs Debt
Where NKTX stands vs its 150-day and 200-day moving averages
As of the July 15, 2026 close, NKTX finished 6.85% above its 150-day moving average ($2.48) and 11.34% above its 200-day moving average ($2.38). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is NKTX overbought or oversold?
At the July 15, 2026 close, NKTX's RSI(14) was 41.4, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $230.4M in cash comfortably exceeding the $75.0M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$57.4M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -30.1% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Nkarta, Inc.'s trajectory.